WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H555174
CAS#: 89-35-0
Description: UBP551 is a potent and selective modulator of NMDA receptors.
Hodoodo Cat#: H555174
Name: UBP551
CAS#: 89-35-0
Chemical Formula: C11H8O4
Exact Mass: 204.04
Molecular Weight: 204.181
Elemental Analysis: C, 64.71; H, 3.95; O, 31.34
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: UBP551; UBP-551; UBP 551.
IUPAC/Chemical Name: 3,5-Dihydroxynaphthalene-2-carboxylic acid
InChi Key: YELLAPKUWRTITI-UHFFFAOYSA-N
InChi Code: YELLAPKUWRTITI-UHFFFAOYSA-N
SMILES Code: O=C(C1=C(O)C=C2C(O)=CC=CC2=C1)O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 204.18 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Monaghan DT, Irvine MW, Costa BM, Fang G, Jane DE. Pharmacological modulation
of NMDA receptor activity and the advent of negative and positive allosteric
modulators. Neurochem Int. 2012 Sep;61(4):581-92. doi:
10.1016/j.neuint.2012.01.004. Epub 2012 Jan 17. Review. PubMed PMID: 22269804;
PubMed Central PMCID: PMC3360989.
2: Costa BM, Irvine MW, Fang G, Eaves RJ, Mayo-Martin MB, Skifter DA, Jane DE,
Monaghan DT. A novel family of negative and positive allosteric modulators of
NMDA receptors. J Pharmacol Exp Ther. 2010 Dec;335(3):614-21. doi:
10.1124/jpet.110.174144. Epub 2010 Sep 21. PubMed PMID: 20858708; PubMed Central
PMCID: PMC2993558.